Remedy Robotics Announces Partnership with SVIN Mission Thrombectomy
97% of stroke patients across the world do not have access to the best care - life-saving and disability-sparing endovascular thrombectomy. Even in the US, only one third of patients can access thrombectomy, often after delays, while in many countries access is often under 1%.
These were the sobering findings of the MT-Glass study conducted by Mission Thrombectomy, underscoring the scale of the challenge in front of us as pursue our mission of making flawless, immediate endovascular care to patients, wherever they are in the world.
We are delighted today to announce that we have agreed a long-term strategic partnership with Mission Thrombectomy to work together in pursuit of this shared mission. Under this partnership Remedy Robotics will become Mission Thrombectomy’s exclusive robotic partner and we will work closely with their incredible clinical team on the testing, development and global roll out of our groundbreaking N1 System.
Read the full press release here
Mission Thrombectomy has been at the forefront of accelerating access endovascular thrombectomy for stroke since 2016. Their world-leading clinical network, which includes regional committees in over 100 countries, and the broader Society of Vascular and Interventional Neurology (SVIN) will provide critical input and support as we develop the N1 System. Their incredible track record leading research, clinician training, guideline development, and global advocacy for endovascular thrombectomy, makes them quite simply the perfect partner for Remedy.
Together we will work to accelerate the deployment of our system and to expand access to thrombectomy across the US and globally.
We will be hosting a live webinar with Mission Thrombectomy on World Stroke Day - Wednesday, October 29, at 9am PT, 12pm ET, to explore our partnership and the future of stroke intervention - sign up here.
